TipRanks
Go Ultimate55% OFF

Nu Skin (NUS) AI Stock Analysis

Top Page

NUS

Nu Skin

(NYSE:NUS)

Select Model
Rating:40Underperform
Price Target:$5.00▲(7.53% Upside)
Action:downgraded
Date:08/11/26

The overall score of 40 reflects Nu Skin's substantial fundamental and technical headwinds. Persistent revenue declines, net losses, and eroding equity base weigh heavily. The stock is in a clear downtrend with no reversal signals. Valuation is unattractive due to negative earnings, overshadowing the high dividend yield. While strategic progress with Prysm iO and cost control, along with a positive shareholder vote on the incentive plan, provide some optimism, these are insufficient to offset the core challenges.

Positive Factors
Prysm iO AdoptionRapid Prysm iO placement and scan growth indicates meaningful engagement with a differentiated wellness consultation tool. Planned AI personalization and higher device penetration could support repeat product demand, improve affiliate conversion, and strengthen customer lifetime value over coming quarters.
Negative Factors
Revenue and Profit DeclineMulti-year revenue contraction combined with a large TTM net loss signals that Nu Skin is not currently generating sufficient operating scale. Prolonged top-line weakness can erode operating leverage, constrain investment capacity, and make a durable earnings recovery more difficult.

Nu Skin Key Performance Indicators (KPIs)

Revenue by SegmentBreaks down sales across the company’s segments so you can see where growth is coming from and how diversified the business is. For Nu Skin, this reveals dependence on specific regions, product categories, or distributor channels, helps identify fast‑growing versus stagnant areas, and flags concentration or seasonal risks that could affect future top‑line momentum.

-$200.00M$0.00$200.00M$400.00M$600.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights

Nu Skin’s revenue mix has shifted: legacy consumer sales in Mainland China and the Americas have trended down, while Manufacturing and the Rhyz/RISE-related lines spiked in 2023–24—helping core gross margins and EPS in 2025—but Rhyz revenues pulled back in 2025 and China/Americas weakness persists, leaving top-line growth fragile. Management’s 2026 guidance is cautious and pins upside on nascent Prism IO device placements and India expansion; monetization and slower consumer adoption remain execution risks, so margin gains may outpace revenue recovery unless subscription conversion accelerates.

Data provided by:The Fly

Nu Skin (NUS) vs. SPDR S&P 500 ETF (SPY)

-60%-50%-40%-30%-20%-10%0%10%20%NUS-54.46%SPY+11.79%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
$226.35M
Dividend Yield
5.16%
Average Volume (3M)
528.09K
Price to Earnings (P/E)
-1.0
Beta (1Y)
1.28
Revenue Growth
-15.44%
EPS Growth
-319.79%
Country
US
Employees
2,800
Sector
Consumer Defensive
Sector Strength
62
Industry
Household & Personal Products

Nu Skin Business Overview & Revenue Model

Company Description

Nu Skin Enterprises, Inc. (NUS) is a global enterprise dedicated to the creation and worldwide distribution of beauty and wellness solutions. The company's diverse product offerings encompass advanced skincare systems, such as the ageLOC Spa and ageL...

How the Company Makes Money

Nu Skin makes money primarily by selling its beauty and wellness products through a direct-selling (multi-level) distribution channel. The company generates revenue when products are purchased from Nu Skin by its independent salesforce (often referre...

Nu Skin Earnings Call Summary

Earnings Call Date:Aug 09, 2026(Q2-2026)|% Change Since:-8.55%|Next Earnings Date:Nov 04, 2026
Earnings Call SentimentNeutral

The call presented a mixed picture: strong product momentum and engagement around Prysm iO, improved core gross margin, cost reductions in G&A, and disciplined liquidity position are notable positives. However, sizable non-cash goodwill and deferred tax charges materially impacted reported earnings, adjusted operating margins declined, recruiting and leadership development remain weak, and the India launch was delayed. Near-term FX headwinds and modest operating cash flow further temper the outlook. On balance, the company shows encouraging strategic traction and product adoption but faces meaningful near-term financial and operational headwinds.

Positive Updates

Quarterly Revenue
Q2 2026 revenue of $320.1 million (includes ~1% / $4M FX headwind). Full-year revenue guidance updated to $1.28–$1.35 billion (FY FX headwind ~1%).

Negative Updates

Significant Non-Cash Accounting Charges
Recorded a $78.9 million non-cash goodwill impairment related to the Rhyz manufacturing reporting unit and a $167.5 million non-cash valuation allowance on U.S. deferred tax assets, producing reported EPS of negative $5.14 for the quarter.

Company Guidance

Nu Skin updated Q3 revenue guidance to $310–$340 million (with an expected 2–3% foreign currency headwind) and Q3 EPS of $0.00–$0.09 reported (adjusted $0.10–$0.20), and revised full‑year revenue to $1.28–$1.35 billion (≈1% FX headwind) with reported FY EPS of −$4.90 to −$4.73 (adjusted $0.70–$0.90) and an adjusted effective tax rate of ~35%; management expects to place 50,000–60,000 Prysm iO devices by year‑end (vs. >39,000 placed to date, up ~30% QoQ, and 2.5 million scans, up ~25% QoQ). The company plans $5–$10 million of cash‑based organizational transition costs through year‑end excluded from adjusted results and also excluded the Q2 non‑cash charges (a $78.9M goodwill impairment and a $167.5M deferred tax valuation allowance) from adjusted guidance; for context Q2 revenue was $320.1M, gross margin 68.2% (core 77.7%), adjusted operating margin 6.1%, cash $189.6M, debt $213.7M and Q2 operating cash flow $10.6M.

Nu Skin Financial Statement Overview

Summary

Nu Skin's financial health is weak. Revenue has declined for five consecutive years, with TTM revenue down 49% from 2021. The company reported a net loss of $216M in TTM, and operating margins are negative. While debt has been reduced and operating cash flow remains positive, the downward trend in cash flow and eroding equity base limit flexibility. The overall financial picture is challenging.

Income Statement

30Negative

Balance Sheet

45Neutral

Cash Flow

40Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue1.38B1.49B1.73B1.97B2.23B2.70B
Gross Profit951.49M1.03B1.18B1.36B1.59B2.02B
EBITDA39.32M262.41M-78.83M204.68M174.97M319.78M
Net Income-216.39M160.20M-146.59M8.60M104.78M147.27M
Balance Sheet
Total Assets1.12B1.41B1.47B1.81B1.82B1.91B
Cash, Cash Equivalents and Short-Term Investments189.64M239.84M197.99M267.82M278.51M354.81M
Total Debt263.74M364.25M478.23M607.33M520.52M503.79M
Total Liabilities578.79M600.07M817.46M984.50M923.67M993.71M
Stockholders Equity542.74M805.24M651.46M821.97M897.30M912.77M
Cash Flow
Free Cash Flow10.78M46.01M70.16M60.15M49.01M72.97M
Operating Cash Flow50.81M80.29M111.74M118.64M108.06M141.58M
Investing Cash Flow-39.60M170.66M-37.96M-134.50M-67.08M-88.73M
Financing Cash Flow-79.16M-202.40M-133.18M10.73M-99.50M-104.70M

Nu Skin Technical Analysis

Technical Analysis SentimentNegative
Last Price4.65

Price Trends

50DMA4.76Negative
100DMA4.91Negative
200DMA6.28Negative

Market Momentum

MACD-0.02Positive
RSI43.27Neutral
STOCH14.19Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUS, the sentiment is Negative. The current price of 4.65 is below the 20-day moving average (MA) of 4.85, below the 50-day MA of 4.76, and below the 200-day MA of 6.28, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 43.27 is Neutral, neither overbought nor oversold. The STOCH value of 14.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for NUS.

Nu Skin Risk Analysis

Nu Skin disclosed 12 risk factors in its most recent earnings report. Nu Skin reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

1 New Risk
1.The information presented below supplements and should be read in conjunction with the detailed discussion of risks associated with our business in our recent SEC filings, including our Annual Report on Form 10-K for the 2024 fiscal year and subsequent reports.Changes to tariff and import/export regulations, and trade disputes between the United States and other jurisdictions have had a negative effect on global economic conditions and could negatively affect our business, financial results and financial condition.The United States and other foreign jurisdictions have changed customs regulations or tariff rates that are applied to our imports or exports, and they could make further changes at any time. Tariff changes are difficult to predict and may cause us material short-term or long-term cost fluctuations. The new political administration in the United States has implemented new tariffs, some of which have been paused but may continue in the future, and has expressed an intention to continue using tariffs more robustly in pursuing government policy. When increases are made to U.S. duty rates or tariffs, retaliatory action by other countries has occurred and could continue occurring. Any increases could impact the price of our products and cause a decline in the demand for our products, as well as cause disruptions in our supply chain. We rely on the use of Free Trade Agreements, where available, that may experience alterations, suspensions or cancellations, which could increase our customs expenses or otherwise harm our business. Although we may take actions in response to tariffs, such as shifting our sourcing and production to alternate locations, there is no assurance that such actions would be successful in mitigating the additional tariffs.In addition to duties and tariffs, any actions taken by the United States or by foreign countries to further implement trade policy changes, including limiting foreign investment or trade, banning imports from particular countries, increasing regulatory requirements, other actions that impact our ability to obtain necessary licenses or approvals, or any other restrictions on international trade, could negatively impact our business. These actions are unpredictable, and any of them could also have a material adverse effect on global economic conditions and the stability of global financial markets, significantly reduce global trade, or restrict our access to suppliers or customers, any of which would have a material adverse effect on our business, financial condition and results of operations.Q2, 2025

Nu Skin Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

NUS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HNSTHNST71Outperform$447.38M-40.25-6.99%―-12.26%-282.39%
ELFELF65Neutral$6.59B111.545.18%―31.23%-42.14%
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
ELEL58Neutral$39.58B214.184.63%1.28%5.51%―
YSGYSG49Neutral$211.05M-6.90-7.20%―25.10%59.14%
ODDODD48Neutral$999.52M72.234.60%―-9.68%-84.42%
NUSNUS40Underperform$226.35M-1.04-29.42%5.16%-15.44%-319.79%

* Consumer Defensive Sector Average

Performance Comparison

-50%0%50%NUSELELFYSGHNSTODDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
NUS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
NUSNu Skin Enterprises4.65-5.68-54.97%
ELEstée Lauder109.2317.2918.80%
ELFe.l.f. Beauty, Inc.111.69-9.25-7.65%
YSGYatsen Holding Ltd.2.25-4.17-64.95%
HNSTHonest Company, Inc.4.170.8124.11%
ODDODDITY Tech Ltd. Class A21.67-22.21-50.62%

Nu Skin Corporate Events

Business Operations and StrategyExecutive/Board Changes

Nu Skin Announces EVP Medical Leave and Sales Oversight

Neutral
Aug 21, 2026

On Aug. 17, 2026, Nu Skin Enterprises, Inc. announced that Executive Vice President and President of Global Sales Justin Keisel began a medical leave of absence. Executive Vice President, Chief Operating Officer and Chief Legal Officer Chayce Clark w...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 11, 2026